8-K: Scilex Subsidiary Semnur Announces $2.5 Billion Merger with Denali Capital Acquisition Corp.

Semnur Pharmaceuticals, a Scilex subsidiary, has agreed to a merger with Denali Capital Acquisition Corp., valuing Semnur at $2.5 billion, to create a publicly traded biopharma company focused on non-opioid pain therapies.

Summary

• Semnur Pharmaceuticals, a wholly-owned subsidiary of Scilex Holding Company, has entered into a merger agreement with Denali Capital Acquisition Corp., a special purpose acquisition company.
• The merger values Semnur at a pre-transaction equity value of $2.5 billion.
• The combined company will be renamed Semnur Pharmaceuticals, Inc. and is expected to trade on Nasdaq under the ticker symbols SMNR and SMNRW.
• The transaction is expected to close by the first quarter of 2025, pending shareholder approval and other closing conditions.
• Semnur is focused on developing non-opioid pain therapies, with its lead product, SP-102 (SEMDEXA), a Phase 3 novel injectable corticosteroid gel for sciatica.
• Independent market research projects annual sales of SEMDEXA in sciatica to reach $1.5 billion to $2.0 billion by the fifth year of launch.
• Scilex is expected to be the majority holder of the combined company.
• The combined company will be led by a management team with proven industry experience.

Sentiment

Score: 8

Explanation: The document is generally positive, highlighting a significant merger, a promising product candidate, and a large market opportunity. The forward-looking statements are optimistic, and the management comments are confident. However, there are also some risks and uncertainties mentioned, which temper the overall sentiment.

Positives

• The merger will provide Semnur with access to public markets and further investment for the development of SP-102 (SEMDEXA).
• SP-102 (SEMDEXA) has completed a Phase 3 trial with positive results, showing a decrease in pain intensity for over a month in sciatica patients.
• The combined company will be led by a management team with proven industry experience.
• The merger is expected to unlock value for Scilex shareholders.

Risks

• The transaction is subject to shareholder approval, regulatory approval, and other closing conditions, which may not be met.
• The projected sales of SEMDEXA are based on market research and may not be achieved.
• The combined company may face challenges in integrating the businesses of Semnur and Denali.
• The combined company may face challenges in obtaining and maintaining the listing of its securities on Nasdaq.

Future Outlook

The Business Combination is expected to close during the first quarter of 2025, following the receipt of the required approval by Denalis shareholders and the satisfaction or waiver of other customary closing conditions.

Management Comments

• Jaisim Shah, Chief Executive Officer and President of Scilex, stated that the business combination will enable the company to advance its growth strategy, including gaining access to public markets and exploring potential partnerships and global pharma collaborations for SP-102 (SEMDEXA).
• Jaisim Shah also highlighted the many milestones achieved by the Scilex team since its Nasdaq debut, including revenue growth in ZTlido, the launch of ELYXYB and Gloperba, and the completion of the Phase 3 study for SP-102 (SEMDEXA).

Industry Context

This announcement reflects a trend of pharmaceutical companies seeking to leverage the public markets for funding and growth, particularly in the area of non-opioid pain management. The merger also highlights the increasing interest in novel therapies for chronic pain conditions like sciatica.

Comparison to Industry Standards

• The projected sales of $1.5 to $2.0 billion for SEMDEXA are ambitious but not unprecedented for a successful drug in a large market like sciatica. For example, AbbVie's Humira, while not a pain medication, achieved peak sales of over $20 billion annually, demonstrating the potential for blockbuster drugs in large therapeutic areas.
• The $2.5 billion valuation for Semnur is significant for a pre-revenue company, but it is not uncommon for companies with promising late-stage clinical assets. For example, several biotech companies with Phase 3 assets have been acquired or merged at valuations in the billions of dollars.
• The use of a SPAC merger is a common route for private companies to go public, particularly in the biotech sector. This allows for a faster and potentially less expensive path to the public markets compared to a traditional IPO. However, SPAC mergers also come with their own set of risks and challenges, including potential shareholder redemptions and market volatility.

Related Party Transactions

• The document mentions that Scilex is expected to be the majority holder of the combined company, indicating a related party transaction.

Stakeholder Impact

• Shareholders of Scilex may benefit from the increased value of their stake in Semnur.
• Shareholders of Denali Capital Acquisition Corp. will have the opportunity to vote on the merger.
• Employees of Semnur may benefit from the increased resources and opportunities provided by the merger.
• Patients with sciatica may benefit from the development and commercialization of SP-102 (SEMDEXA).

Next Steps

• The SPAC will file a registration statement on Form S-4 with the SEC, which will include a proxy statement/prospectus.
• The SPAC will mail a definitive proxy statement/final prospectus to its shareholders.
• The SPAC will hold a special meeting of shareholders to approve the merger.
• The parties will work to satisfy all closing conditions and complete the merger by the first quarter of 2025.

Key Dates

Keywords

Semnur Pharmaceuticals, Denali Capital Acquisition Corp, merger, SP-102, SEMDEXA, sciatica, non-opioid pain therapy, biopharma, Nasdaq, Scilex Holding Company